Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses
- Authors
- Jung, Byeongjin; Kang, Hyejin; Lee, Wonhwa; Noh, Hyun Jin; Kim, You-Sun; Han, Min-Su; Baek, Moon-Chang; Kim, Jaehong; Bae, Jong-Sup
- Issue Date
- Apr-2016
- Publisher
- KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
- Keywords
- Barrier integrity; Dabrafenib; HMGB1; Sepsis
- Citation
- BMB REPORTS, v.49, no.4, pp.214 - 219
- Journal Title
- BMB REPORTS
- Volume
- 49
- Number
- 4
- Start Page
- 214
- End Page
- 219
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8423
- DOI
- 10.5483/BMBRep.2016.49.4.220
- ISSN
- 1976-6696
- Abstract
- A nucleosomal protein, high mobility group box 1 (HMGB1) is known to be a late mediator of sepsis. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Inhibition of HMGB1 and renewal of vascular integrity is appearing as an engaging therapeutic strategy in the administration of severe sepsis or septic shock. Here, we examined the effects of dabrafenib (DAB) on the modulation of HMGB1-mediated septic responses. DAB inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells. In addition, treatment with DAB inhibited the HMGB1 secretion by CLP and sepsis-related mortality and pulmonary injury. This study demonstrated that DAB could be alternative therapeutic options for sepsis or septic shock via the inhibition of the HMGB1 signaling pathway.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8423)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.